Alan M. Garber Sells 19,205 Shares of Exelixis, Inc. (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) Director Alan M. Garber sold 19,205 shares of the stock in a transaction that occurred on Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the transaction, the director now owns 35,703 shares in the company, valued at $857,229.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Exelixis Stock Performance

EXEL opened at $23.61 on Wednesday. The stock has a market capitalization of $7.16 billion, a price-to-earnings ratio of 36.89, a PEG ratio of 0.63 and a beta of 0.53. The company has a fifty day moving average of $21.96 and a 200 day moving average of $21.96. Exelixis, Inc. has a fifty-two week low of $18.08 and a fifty-two week high of $24.34.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.02. The company had revenue of $479.65 million during the quarter, compared to analysts’ expectations of $481.23 million. Exelixis had a net margin of 11.35% and a return on equity of 8.57%. On average, equities research analysts forecast that Exelixis, Inc. will post 1.22 earnings per share for the current year.

Hedge Funds Weigh In On Exelixis

Institutional investors and hedge funds have recently made changes to their positions in the business. American Century Companies Inc. grew its stake in shares of Exelixis by 31.5% in the 3rd quarter. American Century Companies Inc. now owns 1,410,113 shares of the biotechnology company’s stock worth $30,811,000 after buying an additional 338,021 shares in the last quarter. Exchange Traded Concepts LLC grew its stake in shares of Exelixis by 244.5% in the 4th quarter. Exchange Traded Concepts LLC now owns 118,359 shares of the biotechnology company’s stock worth $2,839,000 after buying an additional 83,999 shares in the last quarter. Seven Eight Capital LP grew its stake in shares of Exelixis by 61.7% in the 3rd quarter. Seven Eight Capital LP now owns 21,765 shares of the biotechnology company’s stock worth $476,000 after buying an additional 8,305 shares in the last quarter. NewEdge Wealth LLC purchased a new position in shares of Exelixis in the 3rd quarter worth $10,238,000. Finally, FMR LLC grew its stake in shares of Exelixis by 9.3% in the 3rd quarter. FMR LLC now owns 2,884,424 shares of the biotechnology company’s stock worth $63,025,000 after buying an additional 246,605 shares in the last quarter. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. TheStreet upgraded shares of Exelixis from a “c+” rating to a “b-” rating in a research report on Monday, March 18th. William Blair reiterated an “outperform” rating on shares of Exelixis in a research report on Friday, January 26th. Stifel Nicolaus increased their price target on shares of Exelixis from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Friday, February 2nd. Citigroup started coverage on shares of Exelixis in a research report on Friday, December 15th. They set a “buy” rating and a $31.00 price objective on the stock. Finally, BTIG Research started coverage on shares of Exelixis in a research report on Tuesday, December 19th. They set a “buy” rating and a $27.00 price objective on the stock. Five analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $26.29.

About Exelixis

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.